Zoetis gets FDA conditional approval for cattle screwworm treatment

Zoetis Inc. (NYSE: ZTS) announced it received conditional approval from the U.S. Food and Drug Administration for Dectomax-CA1 Injectable to prevent and treat New World screwworm infestations in cattle.

The conditional approval covers the prevention and treatment of infestations caused by larvae of Cochliomyia hominivorax and prevention of reinfestation for 21 days. The product applies to beef cattle, female dairy cattle under 20 months of age, pregnant beef cows, newborn calves and bulls.

Dectomax-CA1 Injectable is the same doramectin formulation as the existing Dectomax Injectable product. The company stated it will begin distributing 250-milliliter and 500-milliliter bottles with the new label in the first half of 2026.

The New World screwworm poses economic risks to the U.S. agricultural industry estimated in the billions of dollars, according to the press release citing USDA data. The parasite affects livestock health and productivity.

"New World screwworm has the potential to bring unprecedented economic and animal health harm to livestock producers," said Mike Lormore, Director of Cattle and Pork Technical Services at Zoetis.

The product carries a 35-day pre-slaughter withdrawal period for cattle use and cannot be used in female dairy cattle 20 months of age or older. The FDA conditional approval is pending full demonstration of effectiveness under NADA 141-616.

Zoetis reported revenue of $9.3 billion in 2024 and employs approximately 13,800 people worldwide.

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• CoVolt Power files for proposed IPO